Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.

Abstract

OBJECTIVE:

The purpose of this study was to compare the efficacy and safety of insulin glargine and detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus (DM).

METHODS:

Thirty four children and adolescents with type 1 DM (mean age 12.7 ± 3.4 years, diabetes duration 5.4 ± 3.0 years) were included in the study. All patients had been receiving intensive insulin therapy with insulin aspart and NPH for at least 6 months before switching from NPH to insulin glargine (Group 1, n=19) or detemir (Group 2, n=15). The medical records obtained within 6 months before and after treatment with insulin glargine and detemir were retrospectively reviewed and the data were compared in each group.

RESULTS:

The mean age and duration of DM were similar in two groups (p>0.05). In both groups, switching from NPH to insulin glargine or detemir, resulted in a reduction in HbA(1c) (p0.05, for both). Patients in the detemir treated group had less increment in body mass index (BMI) SDS at the end of 6 months of therapy compared to NPH and glargine treated patients (p>0.05, for both). No side effects were noted throughout the study.

CONCLUSION:

Both insulin glargine and detemir improved HbA(1c) at short-term and proved to be safe and well tolerated in children and adolescents with type 1 DM.

• Authors: Bumin Nuri Dündar, Nihal Dündar, Erdal Eren
• Journal: Journal of clinical research in pediatric endocrinology (J Clin Res Pediatr Endocrinol) Vol. 1 Issue 4 Pg. 181-7 ( 2009) ISSN: 1308-5735 [Electronic] Turkey
• PMID: 21274293 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin, Long-Acting
• hemoglobin A1c protein, human
• Insulin Glargine
• Insulin Detemir
• Insulin, Isophane

Topics

• Adolescent
• Blood Glucose (metabolism)
• Body Mass Index
• Child
• Diabetes Mellitus, Type 1 (blood, drug therapy, pathology)
• Female
• Glycated Hemoglobin (metabolism)
• Humans
• Hypoglycemic Agents (adverse effects, therapeutic use)
• Insulin Detemir
• Insulin Glargine
• Insulin, Isophane (adverse effects, therapeutic use)
• Insulin, Long-Acting (adverse effects, therapeutic use)
• Male
• Retrospective Studies
• Treatment Outcome